Detalhe da pesquisa
1.
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Hepatology
; 79(5): 1212-1219, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38445559
2.
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease.
Hepatology
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652636
3.
Increases and decreases in liver stiffness measurements are independently associated with the risk of liver-related events in NAFLD.
J Hepatol
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38762169
4.
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
N Engl J Med
; 385(17): 1559-1569, 2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670043
5.
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.
Clin Gastroenterol Hepatol
; 22(1): 124-134.e1, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061109
6.
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
Gastroenterology
; 165(2): 463-472.e5, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127100
7.
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Clin Gastroenterol Hepatol
; 22(1): 102-112.e9, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088457
8.
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Clin Gastroenterol Hepatol
; 22(1): 113-123.e9, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088458
9.
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
Am J Gastroenterol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587293
10.
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
J Hepatol
; 78(4): 693-703, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528237
11.
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
J Hepatol
; 78(4): 684-692, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36513186
12.
Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
J Hepatol
; 78(2): 238-246, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368598
13.
Inhibition of integrin binding to ligand arg-gly-asp motif induces AKT-mediated cellular senescence in hepatic stellate cells.
Mol Cell Biochem
; 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37902885
14.
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
J Hepatol
; 76(3): 506-517, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34740705
15.
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
Gastroenterology
; 161(5): 1475-1486, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310978
16.
NAFLD: Reporting Histologic Findings in Clinical Practice.
Hepatology
; 73(5): 2028-2038, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33111374
17.
Therapeutic Landscape for NAFLD in 2020.
Gastroenterology
; 158(7): 1984-1998.e3, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32061596
18.
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Hepatology
; 72(4): 1219-1229, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31965579
19.
Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease.
Dig Dis
; 39(3): 247-257, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32836224
20.
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
J Hepatol
; 72(1): 25-33, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31634532